ArticleCureus2025
Beyond Selective Serotonin Reuptake Inhibitor (SSRIs): Exploring Hormonal Therapy for Mood Disorders in Perimenopause and Postmenopause.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Examining New Mothers' Access to Zuranolone.Ochsner journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perimenopause and postmenopause are vulnerable periods for the onset or exacerbation of mood disorders due to fluctuating or persistently low estrogen levels and neurochemical changes. While antidepressants are often first-line treatments, a subset of women may benefit from hormone replacement therapy (HRT), particularly transdermal estradiol. This case report presents two women: one, aged 48, experiencing mood instability during perimenopause with pre-existing depression, and another, aged 55, who developed new-onset depressive symptoms during postmenopause. In both cases, treatment with estradiol alongside careful psychotropic management resulted in marked improvement. These cases highlight the utility of an integrative, hormone-informed approach in managing mood disorders during both perimenopause and postmenopause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.